The Pharmacy Times® Cardiovascular Health Resource Center is a comprehensive resource for clinical news and expert insights on the health of the heart and blood vessels, including coronary heart disease, stroke, heart failure, heart arrhythmias, and heart valve issues.
March 22nd 2023
Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.
Study: Linking Flu Vaccination, Potential Cardiovascular Benefits Increases Vaccination RatesMarch 9th 2023
Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.
Study: Black Women of Childbearing Age Are More Likely to Have High Blood Pressure, Pregnancy RisksMarch 8th 2023
Food insecurity was also higher among Hispanic and Black women compared with White women, with 1 in 4 Black women and 1 in 3 Hispanic women reporting food insecurity.
ACC 2023 Session Highlights Need for Pharmacists in Cardio-Oncology Care TeamsMarch 6th 2023
Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.
Experts Debate Approaches to Oral Anticoagulation After AblationMarch 6th 2023
Findings from the AFFIRM trial found increased risks after stopping oral anticoagulant therapy after rhythm control, and the same is true for stopping treatment with oral anticoagulants after successful ablation.
Bempedoic Acid Reduces Major Adverse Cardiovascular Events in Patients Who Cannot Tolerate StatinsMarch 4th 2023
Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein-cholesterol.
New Data From Trials of Evolocumab, Olpasiran Show Promise for Cardiovascular Disease CareMarch 4th 2023
Patients with atherosclerotic cardiovascular disease who were already receiving statin therapy had a reduction in adverse cardiovascular outcomes with earlier initiation of evolocumab.
Hypertensive Disorders in Pregnancy May Increase Long-Term Risk of Cardiovascular EventsMarch 1st 2023
Clinical guidelines suggest screening for cardiovascular risk factors post-partum in women, however, these recommendations are not closely followed, a new study suggests.
Healthy Lifestyles May Lower Risk of Microvascular ComplicationsFebruary 10th 2023
Study results indicate that exercising, following a high-quality diet, limiting alcohol intake, maintaining a healthy body weight, and not smoking protects those with type 2 diabetes.
Connecting Peripheral Artery Disease, Social Determinants of Health Could Lead to Earlier DiagnosesFebruary 3rd 2023
Peripheral artery disease is more common in Black patients than any other racial or ethnic group, but its potential association with negative social determinants of health is not known.
Despite Fewer Known Risk Factors, Researchers Confirm Higher Risk of Cardiovascular Disease for Individuals with Celiac DiseaseFebruary 2nd 2023
Researchers found a 27% heightened risk of cardiovascular disease for individuals with celiac disease compared with those who didn’t have the condition.
Soybean Protein Blocks LDL Cholesterol Production, Reducing Risks of Metabolic DiseasesJanuary 30th 2023
Consuming soy flour rich in B-conglycinin also promotes liver homeostasis, which may prevent atherosclerosis and fatty liver disease, research results show.
Study Results Link COVID-19 to Higher Risk of Cardiovascular Disease, DeathJanuary 26th 2023
Individuals with the virus had an 81 times higher risk of dying in the first 3 weeks of infection, and that remained 5 times higher for up to 18 months, analysis shows.
FDA to Review Application for Empagliflozin for Adults with Chronic Kidney DiseaseJanuary 26th 2023
In a phase 3 trial, empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo.